Nonalcoholic Steatohepatitis (NASH) Treatment Market size was valued at USD 1,352.1 million in 2021, growing at a CAGR of 36.3% from 2022 to 2028. Nonalcoholic steatohepatitis (NASH) treatment or fatty liver disease develop in the nonalcoholic humans that causes the liver damage which is diagnostically similar to alcoholic hepatitis. Nonalcoholic steatohepatitis may also causes due to glucose intolerance, dyslipidemia, and obesity. Currently a few drugs are available in the market for the treatment of nonalcoholic steatohepatitis treatment. The non-alcoholic steatohepatitis (NASH) market is estimated to rise by double digits over the forecast period, owing to rising demand for optimum NASH therapies, an increase in the prevalence of NASH, and the planned launch of pipeline medications. Furthermore, an increase in the prevalence of diabetes and obesity, as well as increased awareness of NASH in developing regions, is expected to boost market growth during the forecast period. However, the industry is expected to be constrained by poor disease diagnosis and a lack of ideal diagnostic techniques. The leading players in the non-alcoholic steatohepatitis (NASH) industry will find profitable prospects in Asia-Pacific. Growth in diagnostic techniques, rapid rise in prevalence of NASH, economic expansion, and increased demand for NASH therapies are some of the factors driving market growth in Asia-Pacific. Other factors such as rising healthcare infrastructure, emerging economies, and an increasing rate of diagnosis are likely to aid the expansion of the Asia-Pacific nonalcoholic steatohepatitis (NASH) treatment market. Furthermore, rising healthcare awareness in emerging nations such as India and China is propelling the industry forward.